Olaparib With or Without Cediranib vs Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
J. Clin. Oncol 2022 Mar 15;[EPub Ahead of Print], JF Liu, MF Brady, UA Matulonis, A Miller, EC Kohn, EM Swisher, D Cella, WP Tew, NG Cloven, CY Muller, DP Bender, RG Moore, DP Michelin, SE Waggoner, MA Geller, K Fujiwara, SD D'Andre, M Carney, A Alvarez Secord, KM Moxley, MA BookmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.